Substance / Medication

Phenylalanine

Overview

Active Ingredient
phenylalanine
RxNorm CUI
8156

Indications

Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN II SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn II can be administered

Labeler: ICU Medical Inc.Updated: 2025-11-02T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Pharmacy Bulk Package – Not For Direct Infusion.

Contraindications

When this intervention should not be used

This preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Factors Affecting Adherence to a Low Phenylalanine Diet in Patients with Phenylketonuria: A Systematic Review.
Yagudina Roza, Kulikov Andrey, Serpik Vyacheslav et al. · Nutrients · 2024
PMID: 39339717Meta-AnalysisFull text (PMC)
A Comprehensive Study of Disease-Causing Variants in PAH, QDPR, PTS, and PCD Genes in Iranian Patients with Hyperphenylalaninemia: A Systematic Review.
Ghanei Mahmoud, Sadat Fatemi Seyedeh Helia, Hamzehlouei Tayebeh · Hum Hered · 2023
PMID: 36646061Meta-AnalysisFull text (PMC)
Phenylalanine Tolerance over Time in Phenylketonuria: A Systematic Review and Meta-Analysis.
Pinto Alex, Ilgaz Fatma, Evans Sharon et al. · Nutrients · 2023
PMID: 37630696Meta-AnalysisFull text (PMC)
Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG).
Adams April D, Fiesco-Roa Moisés Ó, Wong Lawrence et al. · Genet Med · 2023
PMID: 37470789Meta-Analysis
Cognitive function in untreated subjects with mild hyperphenylalaninemia: a systematic review.
Rostampour Noushin, Chegini Rojin, Hovsepian Silva et al. · Neurol Sci · 2022
PMID: 35729439Meta-Analysis
Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis.
Foreman Pamela K, Margulis Andrea V, Alexander Kimberly et al. · Orphanet J Rare Dis · 2021
PMID: 34082800Meta-AnalysisFull text (PMC)
Tyrosine, phenylalanine, and tryptophan in gastroesophageal malignancy: a systematic review.
Wiggins Tom, Kumar Sacheen, Markar Sheraz R et al. · Cancer Epidemiol Biomarkers Prev · 2015
PMID: 25344892Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Phenylalanine (substance)
SNOMED CT
63004003
UMLS CUI
C0031453
RxNorm CUI
8156
Labeler
ICU Medical Inc.

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.